Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06173076
Other study ID # Y2022-0336
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 18, 2022
Est. completion date December 31, 2032

Study information

Verified date November 2023
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Mei-Ping Ding
Phone +86 0571 87783872
Email dmp-neurology@zju.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases. So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.


Description:

In this prospective study, the investigators are aiming to recruit newly diagnosed patients with anti-LGI1 encephalitis. At the acute stage and during the follow-up, some routine and advanced paraclinical examinations will be conducted, including dynamic blood and/or cerebrospinal fluid (CSF) test, multimodal brain magnetic resonance imaging (MRI) including functional MRI, diffusion tensor imaging, arterial spin labeling, et al), Electroencephalography (EEG) or continuous video-EEG (VEEG), positron emission tomography (PET), neuropsychological tests and some other paraclinical examinations. Through the comprehensive analysis, the clinical outcomes and associated factors are further explored in anti-LGI1 encephalitis.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2032
Est. primary completion date December 31, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Meet the 2016 consensus diagnostic criteria for anti-LGI1 encephalitis. 2. Newly diagnosed, and during the acute stage before study enrollment. 3. Sign the informed consent form. Exclusion Criteria: 1. with the diagnosis of epilepsy, stroke, cerebral trauma, and/or other nervous system disease prior to the onset of encephalitis. 2. with coexisting antibodies, such as anti-contactin-associated protein 2 (CASPR2) antibody. 3. Lost to follow-up.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary seizure outcomes The incidence of different seizure outcomes and associated factors will be analyzed. 1 year, 2 year
Primary Clinical severity and recovery 1 modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome 1 year, 2 year
Primary Clinical severity and recovery 2 clinical assessment scale for autoimmune encephalitis, ranging from 0-27, higher scores mean a worse outcome 1 year, 2 year
Primary Incidence of recurrence a relapse of encephalitis 1 year, 2 year
Secondary Memory assessment 1 the Wechsler Memory Scale, high score means a good memory. 1 year, 2 year
Secondary Memory assessment 2 Rey Auditory Verbal Learning Test (RAVLT), high score means a good vebal episodic memory. 1 year, 2 year
Secondary Brain volume with 3T magnetic resonance imaging (MRI), volumes of the whole hippocampus, hippocampal subfields and other relevant regions were determined using FreeSurfer. The unit of volume is described as mm3. 1 year, 2 year
See also
  Status Clinical Trial Phase
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Completed NCT04708626 - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Not yet recruiting NCT05711563 - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Recruiting NCT06079294 - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism N/A
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT05280600 - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT06033846 - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis Phase 2
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Recruiting NCT05177939 - Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis Phase 3
Active, not recruiting NCT06432803 - Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Recruiting NCT06019975 - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Not yet recruiting NCT06456736 - Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
Completed NCT05825690 - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis